What are your top takeaways from ASCO GU 2025?   

In terms of practice-informing presentations in prostate cancer here are my top 3: GROUQ-PCS 9 trial (Canada, abstract 22). This trial led by Niazi et al tested whether metastasis-directed radiotherapy based on conventional imaging to up to 5 sites provided benefits in delaying rPFS or PSA progress...

The one trial that will impact my practice is the COTRIMS trial, which assessed RPLND in stage 2A and non-bulky stage 2B seminoma. Traditionally, stage 2 seminoma has been treated with radiation or with BEP chemotherapy x3 cycles or EP x4 cycles. However, there is recognition that both chemotherapy ...

1. ABSTRACT LBA18: Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial.  Well done trial, clinically meaningful OS benefit Caveats ...

TALAPRO-2 overall survival data ENZA-P overall survival data Enzalutamide +/- mevrometostat randomized phase 2 trial 

My favorites were Abstract 308 (middle or high veracyte score predicts benefit of dose escalation). Abstract 309 (comparison of 2 trials reveals higher distant metastatic failure rate with a surgical-based approach for high-risk prostate cancer than seen with a radiation-based approach) Abstrac...

Interesting bladder Ca trials at GU ASCO 2025: NIAGARA trial updates  CheckMate 274 trial updates RETAIN-2 trial and also the poster by Ruben Raychaudhuri et al. (aMVAC + pembrolizumab for MIBC with histology subtypes)  EV-302 updates for 1L metastatic disease T-DXd, FGFR inhibitor, T...